 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | SDC1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.
It is the anti-CD138 chimerized MAb (nBT062)[1] linked to the maytansinoid DM4.[1]
It is being investigated as part of a treatment for multiple myeloma.[1]
Clinical trials
[edit]Multiple Myeloma
[edit]Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone.[1] Follow up data reported "encouraging efficacy" in December 2014.[2]
Other
[edit]As of December 2014[update], it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer.[2]
Mechanism of action
[edit]CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells.[1] The antibody part binds to CD138 on the target cells and then the DM4 kills the cell.[citation needed]
See also
[edit]- ImmunoGen, more on DM1/DM4 and the linker used in Indatuximab ravtansine
- Syndecan 1, the protein encoded by SDC1.
References
[edit]- ^ a b c d e Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
- ^ a b Biotest AG: Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone